Zhang
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Zhang is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Recurrence-Free Survival Dynamics Following Adjuvant Chemotherapy for Resected Cancers of the Gastrointestinal Tract: A Systematic Review of Randomized Controlled Trials. · J Surg Res · 2026-08-14
- Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial. · Hemasphere · 2026-08-11
- Zhang: The Other Taxation — Tribes, Territories, and Fiscal Autonomy · TaxProf Blog · 2026-08-09 · usually covers Professional
- GOALI: A Community-Driven Benchmarking Framework for Trustworthy Generative AI in Architecture, Engineering and Construction · nsf · 2026-10-01 · usually covers Federal Alignment
- Conference: Joint Workshop on Secure and Trustworthy Cyberspace (NSF-CSA Singapore) · nsf · 2026-10-01 · usually covers Federal Alignment
- High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring · European Journal of Cancer · 2026-08-16 · usually covers Oncology
What the reporting says
It shows up alongside Colorectal Cancer (49), Wang (12), Chen (11), Immunotherapy (10), AI (16), China (12).
Two steps out: ctDNA (through Colorectal Cancer, 49 shared stories on the weaker link); KRAS (through Colorectal Cancer, 49 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 49 shared stories on the weaker link); Braf (through Colorectal Cancer, 47 shared stories on the weaker link).
Tracked since Apr 3, with coverage on 38 separate days — concentrated in Pubmed Targeted.